JANX

Janux Therapeutics, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001817713 Biotech & Drug Discovery

$16.69 +0.03 (+0.18%)

Oct 26 4:00 PM ET · prev $16.66

Market cap

$1.0B

Small cap

Consensus

Buy

84% Buy or better · 25 analysts

Median target

🔒 Subscribers only

Next earnings

Nov 10

in 14 days · EPS est. −$0.49

1 year

−39.0%

from $27.35 · Oct 27

30 days

+0.7%

from $16.58

52-week range

$12.18–34.74

−52% from high · low Feb 5

Avg volume 20D

766.2K

shares / day

Short interest

🔒 Subscribers only

Insider net

−$85.8K

0 buyers · 2 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 4 reports · latest

Balance 0 bearish · 1 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 3/4 ·Next Earnings date, Nov 10, 2026

Strongest NEUTRAL Janux Therapeutics disclosed the departure of Chief Medical Officer William Go, M.D., Ph.D. on June 23…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Feb 28 Three major passive institutional investors — Morgan Stanley, Wells…
S May 11 1 insider sell $28.9K at $14.17
S Jun 2 1 insider sell $56.9K at $14.03
A Aug 24 Wolfe Research upgrades

Signal stack

Where each data set points today.

InsidersBEARISH

2 insiders sold $85.8K.
InstitutionsBULLISH

Q2 2026: 30 added (0 new), 12 trimmed or exited.
AnalystsBULLISH

21 of 25 rate it Buy or better.
EstimatesRISING

Current-quarter EPS estimate −$0.518 → −$0.488 over 90 days. 4 up, 7 down in 30 days.
TrendRANGE

5% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
FEDERATED HERMES, INC.	DOUBLED	2,352,927	$36.1M
Point72 Asset Management, L.P.	ADD	1,993,837	$30.6M
CITADEL ADVISORS LLC	DOUBLED	1,200,737	$18.4M
D. E. Shaw & Co., Inc.	DOUBLED	1,096,509	$16.8M
GOLDMAN SACHS GROUP INC	ADD	952,675	$14.6M
Qube Research & Technologies Ltd	DOUBLED	702,057	$10.8M
MILLENNIUM MANAGEMENT LLC	ADD	504,544	$7.7M
HRT FINANCIAL LP	ADD	491,001	$7.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

25 analysts

Buy 84% rate it Buy or better

Strong Buy9Buy12Hold3Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Aug 24, 2026	Wolfe Research UPGRADE	UPGRADE	Outperform
Aug 7, 2026	Guggenheim MAINTAIN	MAINTAIN	Buy
May 8, 2026	Piper Sandler MAINTAIN	MAINTAIN	Overweight
May 8, 2026	Wedbush MAINTAIN	MAINTAIN	Outperform
May 8, 2026	Guggenheim MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

bought · 0 insiders

$85.8K

sold · 2 insiders

Date	Insider	Type	Value
Jul 31, 2026	Campbell David Alan President and CEO	GIFT	123,840 sh
Jul 8, 2026	Campbell David Alan President and CEO	EXERCISE	$29.5K
Jun 11, 2026	DOBMEIER ERIC Director	AWARD	15,500 sh
Jun 11, 2026	DOBMEIER ERIC Director	AWARD	5,500 sh
Jun 11, 2026	CAPPS VICKIE L Director	AWARD	5,500 sh
Jun 11, 2026	Barrett Ronald W Director	AWARD	5,500 sh
Jun 11, 2026	Barrett Ronald W Director	AWARD	15,500 sh
Jun 11, 2026	CAPPS VICKIE L Director	AWARD	15,500 sh

Earnings setup

Estimates

Nov 10

reports in 14 days

−$0.49

EPS estimate, this quarter

+6%

estimate change, 90 days

4↑ 7↓

revisions, 30 days

Current-quarter EPS estimate

−$0.518

90d

−$0.500

60d

−$0.488

30d

−$0.488

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.49	-$0.67–-$0.04	+0.0%	$6.4M
Next Q	-$0.57	-$0.81–-$0.32	+0.0%	$7.3M
Current FY	-$1.73	-$2.29–-$0.97	+0.0%	$29.4M
Next FY	-$2.62	-$3.17–-$2.06	+0.0%	$8.1M